Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Elisabetta SautaMarie RobinMatteo BersanelliErica TravaglinoManja MeggendorferLin-Pierre ZhaoJuan Carlos Caballero BerrocalClaudia SalaGiulia MaggioniBernardi MassimoCarmen Di GraziaLuca VagoGiulia RivoliLorenza BorinSaverio D'AmicoCristina Astrid TentoriMarta UbezioAlessia CampagnaAntonio RussoDaniele ManninaLuca LaninoPatrizia ChiusoloLuisa GiacconeMaria Teresa Teresa VosoMarta RivaEsther Natalie OlivaMatteo ZampiniElena RivaOlivier NibourelMaria Elena BicchieriNiccolo' BolliAlessandro RambaldiFrancesco PassamontiVictor SavevskiArmando SantoroUlrich GermingShahram KordastiValeria SantiniMaria Diez-CampeloGuillermo F SanzFrancisco SoléWolfgang KernUwe PlatzbeckerLionel AdesPierre FenauxTorsten HaferlachGastone C CastellaniMatteo Giovanni Della PortaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.